Deubiquitinating Enzymes in Alzheimer’s Disease: From Protein Homeostasis to Diverse Pathological Processes
- 1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
- 2Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder involving multiple pathological processes, including amyloid-β (Aβ) accumulation, tau pathology, impaired autophagy, mitochondrial dysfunction, neuroinflammation, and synaptic dysfunction. Deubiquitinating enzymes (DUBs) reverse ubiquitination and regulate protein stability, degradation, and cellular signaling. Although studies of DUBs in AD have largely focused on Aβ metabolism and tau homeostasis, accumulating evidence implicates DUBs in a broader range of AD-related processes, including autophagy, neuroinflammation, mitochondrial function, and synaptic function. Several DUBs have also been implicated in more than one of these processes, although these effects have often been identified in different experimental models. In this review, we summarize current knowledge of DUBs in major AD-related pathological processes and discuss the mechanisms through which individual DUBs may influence different aspects of AD pathology. We also discuss the limitations of current studies and the potential and challenges of targeting DUBs in AD.
Related
- Cardiomyocyte-enriched OTUD5 alleviates pathological myocardial hypertrophy by deubiquitinating STAT3 and modulating the STAT3–PGC-1α axis
- Pathological microenvironment-responsive nano-glycospheres restore disc homeostasis by combinatorial metabolic and genetic regulation.
- Nanomaterial modulation of lysosomal homeostasis in neurodegenerative proteinopathies: from pathological-protein degradation to re-release and seeding
- Design, synthesis, and biological activity studies of novel iron-chelating hybrids targeting pathological pathways associated with Alzheimer’s disease.
- Unraveling changes in mitochondrial processes influenced by ancestry in APOEε4 carriers with Alzheimer disease
BibTeX
@article{shi2026deubiquitinating,
title = {{Deubiquitinating Enzymes in Alzheimer’s Disease: From Protein Homeostasis to Diverse Pathological Processes}},
author = {Xueying Shi and Guilin Chen and Xiufeng Wang and Rong Ma and Gang Li},
journal = {Biomolecules},
year = {2026},
month = oct,
doi = {10.3390/biom16101494},
url = {https://www.mdpi.com/2218-273X/16/10/1494},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Deubiquitinating Enzymes in Alzheimer’s Disease: From Protein Homeostasis to Diverse Pathological Processes
AU - Xueying Shi
AU - Guilin Chen
AU - Xiufeng Wang
AU - Rong Ma
AU - Gang Li
PY - 2026
DA - 2026/10/01
JO - Biomolecules
DO - 10.3390/biom16101494
UR - https://www.mdpi.com/2218-273X/16/10/1494
AB - Alzheimer’s disease (AD) is a neurodegenerative disorder involving multiple pathological processes, including amyloid-β (Aβ) accumulation, tau pathology, impaired autophagy, mitochondrial dysfunction, neuroinflammation, and synaptic dysfunction. Deubiquitinating enzymes (DUBs) reverse ubiquitination and regulate protein stability, degradation, and cellular signaling. Although studies of DUBs in AD have largely focused on Aβ metabolism and tau homeostasis, accumulating evidence implicates DUBs in a broader range of AD-related processes, including autophagy, neuroinflammation, mitochondrial function, and synaptic function. Several DUBs have also been implicated in more than one of these processes, although these effects have often been identified in different experimental models. In this review, we summarize current knowledge of DUBs in major AD-related pathological processes and discuss the mechanisms through which individual DUBs may influence different aspects of AD pathology. We also discuss the limitations of current studies and the potential and challenges of targeting DUBs in AD.
SN - 2218-273X
ER -